PDF
ePub
Citation
Print
Abstract
Prolonged thyroid-stimulating hormone (TSH) suppression caused by exogenous subclinical thyrotoxicosis has been reported to impose harmful effects on cardiovascular system. Those effects involve increase in heart rate and myocardial mass, impaired ventricular diastolic and systolic function, decreased exercise capacity, decreased arterial elasticity, development of atrial tachyarrhythmia, and increase in cardiovascular adverse events. Tailored dose adjustment of thyroid hormone under the guidance of TSH level for obviating oversuppression of TSH, and use of beta blockers can reduce cardiovascular adverse effects in patients who undergo thyroid hormone therapy.
References
1. Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E. Braunwald's heart disease. 2011. 9th ed. Philadelphia: Saunders Elsevier.
2. Oh JK, Seward JB, Tajik AJ. The echo manual. 2006. 3rd ed. Rochester: Lippincott Williams & Wilkins.
3. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997. 30(2):474–480.
4. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997. 30(6):1527–1533.
5. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986. 57(6):450–458.
6. Everts ME, Verhoeven FA, Bezstarosti K, Moerings EP, Hennemann G, Visser TJ, et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology. 1996. 137(10):4235–4242.
7. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001. 344(7):501–509.
8. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab. 2000. 85(1):159–164.
9. Smit JW, Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bleeker GB, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2005. 90(11):6041–6047.
10. Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid. 2006. 16(4):381–386.
11. Abdulrahman RM, Delgado V, Ng AC, Ewe SH, Bertini M, Holman ER, et al. Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. Eur J Endocrinol. 2010. 163(3):435–441.
12. Gullu S, Altuntas F, Dincer I, Erol C, Kamel N. Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol. 2004. 150(5):655–661.
13. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994. 78(5):1028–1033.
14. Fazio S, Biondi B, Carella C, Sabatini D, Cittadini A, Panza N, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab. 1995. 80(7):2222–2226.
15. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001. 358(9285):861–865.
16. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010. 95(1):186–193.
XML Download